What happened
Curiox Biosystems filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$827K (+18.07% year on year), an operating loss of US$3.13M and a net loss of US$3.4M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$827K |
|---|---|
| Revenue vs a year earlier | +18.07% |
| Operating profit | −US$3.13M |
| Net income | −US$3.4M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-08-06, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260806900405 → open original filing |
Source: DART. Information only, not investment advice.